{
    "Allocation": "N/A",
    "CompleteTime": 62,
    "DesignModel": "Single Group Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "rc48- adc: d2\uff0cq2w  , ",
                "ArmGroupLabel": "test group",
                "ArmGroupType": "Experimental",
                "InterventionDescription": [
                    {
                        "Dosage": "3mg / kg",
                        "DrugName": "rc48- adc",
                        "Duration": "",
                        "HowToTake": "",
                        "OtherName": [
                            "Triplizumab"
                        ]
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "drug: rc48- adc"
                    ]
                }
            }
        ]
    },
    "Enrollment": "30",
    "InterventionName": "",
    "Masking": "None (Open Label)",
    "NCTID": "NCT05356351",
    "Objective": "An Open-label, Single-arm, Multicenter Phase II Clinical Study\uff1a Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer",
    "OfficialTitle": "An Open-label, Single-arm, Multicenter Phase II Clinical Study\uff1a Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer",
    "PopulationBox": {
        "Condition": "Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "75 Years",
        "MinAge": "18 Years",
        "Participant": "30"
    },
    "PopulationRatio": "",
    "Title": "An Open-label, Single-arm, Multicenter Phase II Clinical Study\uff1a Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer",
    "WashoutPeriod": "",
    "_id": "NCT05356351",
    "version": "1.7.1"
}